David Scheinberg



The overall goals of this laboratory are to develop novel targeted immunotherapies based on effectors of the immune system and to understand their mechanisms of action as well as the mechanisms of resistance to them. This includes antibodies, targeted nano-devices, and active specific agents such vaccines. An important goal is to take these new therapies into human clinical trials for testing. We developed a molecular nanogenerator that releases alpha particles inside cancer cells, now being tested in humans. Read full article in Science (Science, 2001) and a WT1 vaccine, also in national trials (Blood, 2010.) 

We have developed targeted alpha particle therapies, targeted beta emitters, oncogenic protein peptide vaccines, each of which reached human clinical trials; More recently we have discovered TCR mimic antibodies to intracellular proteins (Science Trans. Med., 2013,) as well as prototype targeted nano-machines (Nature Nano, 2013)

Research Topics

Need more info?
Ask a question
Follow us on

Weill Cornell Medicine Graduate School of Medical Sciences 1300 York Ave. Box 65 New York, NY 10065 Phone: (212) 746-6565 Fax: (212) 746-5981